Roger Brown, MD
Psychiatry · Mandeville, LANPI 1538269683
Payments from drug & device makers
Across 1,166 payments — averaging $185.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$132K
- AbbVie$70K
- Corium, LLC$3K
- Tris Pharma Inc$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $7K from 25 others
What the payments were for
- Consulting fees$9600%
- Speaking & faculty fees$184,32585%
- Travel & lodging$12,2076%
- Food & beverage$18,3669%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 371 | $131,532 |
| AbbVie(2 entities) | 192 | $70,155 |
| Corium, LLC | 38 | $3,415 |
| Tris Pharma Inc | 84 | $1,605 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $1,059 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $1,043 |
| Noven Therapeutics, LLC | 67 | $1,014 |
| Axsome Therapeutics, Inc. | 40 | $878 |
| Otsuka America Pharmaceutical, Inc. | 32 | $826 |
| Lundbeck LLC | 39 | $635 |
| Ironshore Pharmaceuticals Inc. | 33 | $614 |
| Neos Therapeutics, LP | 25 | $456 |
| Johnson & Johnson | 21 | $404 |
| Neuronetics, Inc. | 13 | $352 |
| Collegium Pharmaceutical, Inc. | 16 | $335 |
| Idorsia Pharmaceuticals US Inc | 17 | $268 |
| Alkermes, Inc. | 8 | $248 |
| Shire North American Group Inc | 9 | $158 |
| Jazz Pharmaceuticals Inc. | 8 | $152 |
| Bausch Health US, LLC | 7 | $118 |
| Arbor Pharmaceuticals, Inc. | 6 | $104 |
| Eisai Inc. | 6 | $104 |
| Vertical Pharmaceuticals, LLC | 5 | $92 |
| Teva Pharmaceuticals USA, Inc. | 5 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| Adlon Therapeutics L.p. | 3 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Alfasigma USA, Inc. | 2 | $35 |
| Aytu Biopharma, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Rhodes Pharmaceuticals L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$215,891 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 14 | $114,384 |
| VraylarCariprazine Hcl | 42 | $56,494 |
| QelbreeViloxazine Hcl | 18 | $14,700 |
| VyvanseLisdexamfetamine Dimesylate | 31 | $10,884 |
| EdluarZolpidem Tartrate | 12 | $5,012 |
| Lisdexamfetamine Dimesylate | 14 | $4,222 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 96 | $3,256 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 62 | $2,854 |
| Atomoxetine Hcl | 19 | $1,973 |
| Divalproex Sodium ErDivalproex Sodium | 40 | $1,440 |
| Clonazepam | 106 | $1,350 |
| Fluvoxamine Maleate | 14 | $872 |
| Aripiprazole | 42 | $778 |
| Duloxetine Hcl | 31 | $652 |
| Methylphenidate Hcl | 25 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza | $404 | $114,38414 claims |
| AbbVieVraylar | $70,155 | $56,49442 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $131,532 | $14,70018 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $1,059 | $10,88431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Mandeville
- William ColombMandeville$117K
- Shanmugan ShanthaMandeville$7K
- Kashinath YadalamLake Charles$3.8M
- Guy BrannonShreveport$1.4M
- Patrick HayesLake Charles$853K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.